Tools   Select Another Resource Report Type

http://data-analysis.charite.de/care/

Comprehensive database of cancer relevant proteins and compound interactions supported by experimental knowledge.Knowledgebase for drug-target relationships related to cancer as well as for supporting information or experimental data.

Proper citation: CancerResource (RRID:SCR_011945) Copy   

•   Source: SciCrunch Registry

https://genome-cancer.ucsc.edu/

A suite of web-based tools to visualize, integrate and analyze cancer genomics and its associated clinical data. It is possible to display your own clinical data within one of their datasets.

Proper citation: UCSC Cancer Genomics Browser (RRID:SCR_011796) Copy   

•   Source: SciCrunch Registry

http://www.cancerrxgene.org/

A genomics database project is an academic research program to identify molecular features of cancers that predict response to anti-cancer drugs.

Proper citation: Genomics of Drug Sensitivity in Cancer (RRID:SCR_011956) Copy   

•   Source: SciCrunch Registry

http://cbbiweb.uthscsa.edu/KMethylomes/

Datbase and web-based system for visualization and analysis of genome-wide methylation data of human cancers.

Proper citation: Cancer Methylome System (RRID:SCR_012013) Copy   

•   Source: SciCrunch Registry

http://dbcat.cgm.ntu.edu.tw/

A database of CpG islands and analytical tools for identifying comprehensive methylation profiles in cancer cells.

Proper citation: DBCAT (RRID:SCR_012014) Copy   

•   Source: SciCrunch Registry

http://www.cravat.us/

A web-based application designed with an easy-to-use interface to facilitate the high-throughput assessment and prioritization of genes and missense alterations important for cancer tumorigenesis.

Proper citation: CRAVAT (RRID:SCR_012776) Copy   

•   Source: SciCrunch Registry

http://www.tumorbank.org/index.php

Since 1995 the Tumorbank Basel Foundation (German: Stiftung Tumorbank Basel) is a non-for-profit foundation acting in cancer translation research. The purpose of the Tumorbank Basel Foundation is to support in promoting optimization of decision making process for the management of solid cancer personalized treatment modalities to the benefit of the patient. Our Aims: * Acquisition and storage of biological material and clinical data of patients suffering of solid cancer diseases in particular breast and prostate cancer. * Promoting and supporting cancer research using the acquired material and data for clinical studies and translational research. * The development of molecular tumor analyses / tools for cancer patients and the performance of the resulting diagnostic services for personalized treatment modalities. The Tumorbank Basel Foundation has acquired * Data about more than 10''000 breast cancer patients * Data comprise clinical and pathological (histology & IHC) characteristics and biochemical (continuous quantified protein expression levels) features, which are available for almost all samples as well as clinical follow-ups now available for more than 2''000 patients * The RNA expression level of 65 genes has been assessed in >800 samples by Real-Time PCR (317 retrospectively in cases with follow-up, the remaining on a routine basis, prospectively since 2004) The Tumorbank Basel Foundation is storing in Freezers at - 80 degrees C * Ca. 6''000 fresh frozen tissue samples of breast cancer patients * Ca. 9''000 particulate fractions (cytosol / membrane) of all samples analyzed * Ca. 1''000 paired non-malignant adjacent tissue material samples * More than 1''000 extracted RNA samples of good quality * Serum and plasma collection from patients has been started since 2005 All data are stored in a relational SQL data bank using an application. The Tumorbank Basel Foundation is collaborating with several pathology institutes allowing to perform studies correlating results obtained from fresh frozen and paired paraffin embedded tissue samples. The Tumorbank Basel Foundation has started a prostate carcinoma project in Collaboration with the ZeTuP (www.zetup.ch) and pathology institute of St. Gallen. Fresh frozen samples of more than 150 prostate carcinoma patients have been collected and are under investigation.

Proper citation: Tumorbank Basel Foundation (RRID:SCR_004962) Copy   

•   Source: SciCrunch Registry

http://worldbiobank.net/

Founded by the physician partners of ACORN, Inc. (Accelerated Community Oncology Research Network), World BioBank embraces forward-thinking technology and a strong commitment to the advancement of bioscience. The World BioBank collects cancer samples, normal samples, and other non-neoplastic diseases. Data available include sample-specific data, patient-specific data, and study-related data. * SOLID TISSUES (snap frozen and matched formalin-fixed paraffin embedded diseased and normal internal controls) from: Surgical resections, Image-guided biopsies, Bone marrow biopsies, Endoscopic biopsies * LIQUID TISSUES: Peripheral blood, Genomic DNA (from buffy coat), Plasma, Serum World BioBank is committed to marrying samples to a wealth of longitudinal medical data and tissue-specific data.

Proper citation: World BioBank (RRID:SCR_004958) Copy   

•   Source: SciCrunch Registry

http://www.sc.edu/cancer_research/bioSystem.php

The South Carolina Biorepository System (SCBS), directed by Dr. Phil Buckhaults, School of Medicine, is a statewide tissue bank working with health care facilities across South Carolina to collect tumor and matched normal tissue samples from patients with cancer, and providing these samples to researchers statewide. All specimens are de-identified to protect patient privacy, but are annotated with essential, detailed clinical data. Currently, the SCBS inventory includes specimens from the leading types of cancers in South Carolina: breast, colorectal, lung, and prostate, as well as many other cancer sites. The ultimate goal is to improve the lives of cancer patients and their families.

Proper citation: South Carolina Biorepository System (RRID:SCR_005034) Copy   

•   Source: SciCrunch Registry

http://www.rbta.es/

THIS RESOURCE IS NO LONGER IN SERVICE, documented on July 16, 2013. Located in Spain, the Andalusian Regional Tumour Bank is a regional tumor bank. In the last decades cancer knowledge is growing exponentially due human genome knowledge and technological advantages. However, this disease is the biggest problem of health in Europe, with more than 2,5 million new cases per year. The diagnosis and treatment of cancer is now allowing to identify the characteristics that the disease has on each person. The next step is meant to be a great revolution in the treatment of cancer. This scientific development is dependent on the availability of human tumour samples preserved in demanding conditions. Current technology requires the availability of tissue morphological and molecular conditions similar to those that had the sample before being removed. Tumor banks are responsible for these new quality requirements to foster the development of research and health care of patients.

Proper citation: Andalusian Regional Tumour Bank (RRID:SCR_004885) Copy   

•   Source: SciCrunch Registry

https://htrn.osu.edu/Pages/Default.aspx

Collect, bank, and distribute human tissue and fluid specimens by uniting tissue-based research resources within the OSU Department of Pathology and promoting collaborative research within the OSU Medical Center and related national human research projects. The HTRN is comprised of the Pathology Core Facility (PCF), Tissue Archive Service (TAS), Tissue Procurement Service (TPS), AIDS and Cancer Specimen Resource (ACSR), the Cancer and Leukemia Group B Pathology Coordinating Office (CALGB - PCO), and an Adenoma Polyp Tissue Bank (APTB).

Proper citation: Human Tissue Resource Network (RRID:SCR_004785) Copy   

•   Source: SciCrunch Registry

http://www.bumc.bu.edu/busm-pathology/pathology-core-services/biospecimen-archive-research-core-barc/

Biospecimen repository of normal and diseased human material from a variety of tissues and conditions along with clinical annotation. Both frozen aliquots and paraffin embedded tissue are available. Biospecimens are available to qualified researchers with IRB approval. * Preliminary inquires please contact Cheryl Spencer at cheryl.spencer (at) bmc.org

Proper citation: Boston University Biospecimen Archive Research Core (RRID:SCR_005363) Copy   

•   Source: SciCrunch Registry

http://www.einstein.yu.edu/centers/ictr/

Patient-derived specimens are essential to research in genomics, proteomics, and biomarkers. We provide banking for biological fluid and tissue specimens as well as human DNA and RNA. We provide secure archival sample storage as well as clinically-annotated specimen biobanks for defined research projects. The core serves the human research blood and tissue banking needs of clinical and translational researchers. Samples can be banked by an individual PI or by a consortium of investigators. All samples are tracked and archived using a secure tracking database, the Einstein-Montefiore Bio-Repository Databank (EM-BRED), http://informatics30.aecom.yu.edu/em-bred/default.aspx. EM-BRED provides qualified investigators with a solution to securely link patient specimens to clinical and pathological data. It consists of a user-friendly query engine that allows for comprehensive specimen search, and ultimately to build clinical annotations of relevance. The facility works under the best practices set out by NCI and ISBER (2006) for collection, storage, and retrieval of human biological materials for research.

Proper citation: Einstein-Montefiore Institute for Clinical and Translational Research Biorepository (RRID:SCR_005297) Copy   

•   Source: SciCrunch Registry

http://omniBiomarker.bme.gatech.edu

omniBiomarker is a web-application for analysis of high-throughput -omic data. Its primary function is to identify differentially expressed biomarkers that may be used for diagnostic or prognostic clinical prediction. Currently, omniBiomarker allows users to analyze their data with many different ranking methods simultaneously using a high-performance compute cluster. The next release of omniBiomarker will automatically select the most biologically relevant ranking method based on user input regarding prior knowledge. The omniBiomarker workflow * Data: Gene Expression * Algorithms: Knowledge-Driven Gene Ranking * Differentially expressed Genes * Clinical / Biological Validation * Knowledge: NCI Thesaurus of Cancer, Cancer Gene Index * back to Algorithms

Proper citation: omniBiomarker (RRID:SCR_005750) Copy   

•   Source: SciCrunch Registry

http://ki.se/ki/jsp/polopoly.jsp?d=29332&a=31537&l=en

THIS RESOURCE IS NO LONGER IN SERVICE, documented on April 4, 2014. Tissue Biobank collects samples from different types of cancers patients prospectively. Blood samples are being sent to KI Biobank for DNA extraction and storage. Number of sample donors: 611 (June 2010)

Proper citation: KI Biobank - Tissue Biobank (RRID:SCR_006043) Copy   

•   Source: SciCrunch Registry

http://biobankireland.com/

Biobank Ireland Trust promotes the development of an Irish Hospital Biobank Network to coordinate collection of small samples of cancer and normal tissue and coded patient data from those having a cancer operation. This will facilitate international molecular research collaborations, which may help identify the best treatment for each individual patient - personalized medicine. Biobank Ireland is promoting the development of a Hospital Biobank Network throughout the island of Ireland as a bridge between cancer research and care. This new infrastructure will facilitate large national and international translational research collaborations that will raise Ireland''s research profile and benefit those with cancer. Researchers will have online access to samples and to restricted patient data from participating hospitals and an equitable withdrawal process for scientifically and ethically approved projects. Important research results will be explained to the public. Other Objectives: * To facilitate (inter)national translational research collaborations that may lead to new tests and better, less toxic treatments for those with cancer * To enable molecular research on cancer tissue from clinical trials patients identify the best treatment for each individual patient ������??personalized medicine������?? * Researchers will have online access to samples and restricted patient data from participating hospitals, and a fair release process for scientifically and ethically approved projects * Biobank Ireland recognizes the need to have harmonization in biobanking around the world * Important research results will be explained to the public * Biobank Ireland will seek to have the hospital-based Biobank Network funded by government as standard of care

Proper citation: Biobank Ireland Trust (RRID:SCR_006430) Copy   

•   Source: SciCrunch Registry

http://cancer.osu.edu/research/cancerresearch/sharedresources/ltb/Pages/index.aspx

The OSU Comprehensive Cancer Center Leukemia Tissue Bank Shared Resource (LTBSR) facilitates the successful translation of basic leukemia research to the clinical setting via an extensive repository of tissue samples and accompanying pathologic, cytogenetic and clinical data for ready correlation of clinical and biological results. The LTBSR, which is an NCI-sponsored biorepository, has more than 40,000 vials of cryopreserved viable cells and 13,000 vials of matched frozen plasma and/or serum samples from more than 4,000 patients treated for leukemia and other malignancies. Committed to furthering translational research efforts for OSUCCC - James members and the cancer research community, the LTBSR provides investigators with training and technical support as well as procurement, processing, storage, retrieval and distribution of clinical research materials. In many cases, the LTBSR serves as the central processing lab for multi-site trials in which the principal investigator is an OSUCCC - James member. The LTBSR's goals are to: * Provide a central collection, processing and a state-of-the-art repository for samples collected from leukemia patients treated on OSUCCC - James protocols, and * Provide materials to investigators involved in collaborative studies with OSU, who examine relevant cellular and molecular properties of leukemia and correlate these properties with clinical or population-based outcomes.

Proper citation: Ohio State Leukemia Tissue Bank (RRID:SCR_000529) Copy   

•   Source: SciCrunch Registry

http://pstiing.icr.ac.uk/

A publicly accessible knowledgebase about protein-protein, protein-lipid, protein-small molecules, ligand-receptor interactions, receptor-cell type information, transcriptional regulatory and signal transduction modules relevant to inflammation, cell migration and tumourigenesis. It integrates in-house curated information from the literature, biochemical experiments, functional assays and in vivo studies, with publicly available information from multiple and diverse sources across human, rat, mouse, fly, worm and yeast. The knowledgebase allowing users to search and to dynamically generate visual representations of protein-protein interactions and transcriptional regulatory networks. Signalling and transcriptional modules can also be displayed singly or in combination. This allow users to identify important "cross-talks" between signalling modules via connections with key components or "hubs". The knowledgebase will facilitate a "systems-wide" understanding across many protein, signalling and transcriptional regulatory networks triggered by multiple environmental cues, and also serve as a platform for future efforts to computationally and mathematically model the system behavior of inflammatory processes and tumourigenesis.

Proper citation: pSTIING (RRID:SCR_002045) Copy   

•   Source: SciCrunch Registry

http://frederick.cancer.gov/

United States federally funded research and development center supported by the National Cancer Institute and managed by the private contractor Leidos Biomedical Research.

Proper citation: Frederick National Laboratory for Cancer Research (RRID:SCR_011245) Copy   

•   Source: SciCrunch Registry

http://purl.bioontology.org/ontology/CTCAE

A coding system for reporting adverse events that occur in the course of cancer therapy. It was derived from the Common Toxicity Criteria (CTC) v2.0 and is maintained by the Cancer Therapy Evaluation Program (CTEP) at the National Cancer Institution (NCI).

Proper citation: Common Terminology Criteria for Adverse Events (RRID:SCR_010296) Copy   

•   Source: SciCrunch Registry